home / stock / cydy / cydy news

CYDY News and Press, CytoDyn Inc From 06/13/19

Stock Information
Company Name: CytoDyn Inc
Stock Symbol: CYDY
Market: OTC
Website: cytodyn.com
Menu
CYDY CYDY Quote CYDY Short CYDY News CYDY Articles CYDY Message Board
Get CYDY Alerts

News, Short Squeeze, Breakout and More Instantly...
CYDY - CytoDyn to Present Pivotal Data at ASM Microbe 2019 Demonstrating Efficacy and Safety of Leronlimab (PRO 140) in HIV Patients with Multiple ARV Class Resistance

VANCOUVER, Washington, June 13, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications a...
CYDY - CytoDyn: Uncovering An Opportunity

I discovered CytoDyn (CYDY) when performing research for an article on Progenics Pharmaceuticals (PGNX). As I was reading through PGNX SEC filings, I saw a few references to Leronlimab (PRO 140) , a fully humanized monoclonal antibody treatment for HIV that CytoDyn acquired from Progenics b...

CYDY - CytoDyn and FDA Will Meet to Potentially Finalize Protocol for Pivotal Monotherapy Trial for Leronlimab

VANCOUVER, Washington, June 07, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, an...

CYDY - CytoDyn to Present at the 9th Annual LD Micro Invitational Conference on June 5

VANCOUVER, Washington, May 30, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today ...
CYDY - CytoDyn to Hold Investment Community Conference Call on May 20, 2019

VANCOUVER, Washington, May 16, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) announces that Nader Pourhassan, Ph.D., President and Chief Executive Officer, and Richard Pestell, M.D., Ph.D., M.B.A., F.A.C.P., F.R.A.C.P., Chief Medical Officer and Vice Chairman of the Board of Direct...

CYDY - CytoDyn Files Pivotal Trial Protocol for HIV Monotherapy with FDA

After four years of monotherapy trials, data is now available to submit the long-anticipated pivotal trial for monotherapy to the FDA Trial will include 10 weeks of induction therapy to identify which patients are likely to respond and which patients can safely return to their origina...

CYDY - Progenics: Joining The Tired Ranks Of Investors

In my last Progenics Pharmaceuticals ( PGNX ) article , I laid out my reasoning for starting a pilot position prior to the Q4/2018 ER. The share price was bargain-basement levels and the company's projected revenue was attractive. I was confident in the technical entry and the approaching ear...
CYDY - CytoDyn Initiates Pre-Clinical Study of Leronlimab (PRO 140) to Prevent NASH with The Cleveland Clinic's Dr. Daniel J. Lindner, M.D., Ph.D.

VANCOUVER, Washington, May 13, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, ann...

CYDY - CytoDyn Provides Updated Pre-Clinical Data Showing Leronlimab (PRO 140) Continues to Suppress Breast Cancer Metastatic Burden >98% Compared with Untreated Animals

Data supports Orphan Drug Designation filing for mTriple-Negative Breast Cancer   With recently granted Fast Track Designation for mTNBC, Section 561A(f)(2) of the FD&C Act, now requires leronlimab to be available within 15 days under expanded access policy for patients with ...

CYDY - FDA Grants CytoDyn Fast Track Designation for Leronlimab (PRO 140) in metastatic Triple-Negative Breast Cancer, an Unmet Medical Need

VANCOUVER, Washington, May 07, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, tod...
Previous 10 Next 10